Nicolas Martin

1.5k total citations
50 papers, 711 citations indexed

About

Nicolas Martin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Nicolas Martin has authored 50 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 13 papers in Genetics. Recurrent topics in Nicolas Martin's work include Pulmonary Hypertension Research and Treatments (16 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Hemoglobinopathies and Related Disorders (8 papers). Nicolas Martin is often cited by papers focused on Pulmonary Hypertension Research and Treatments (16 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Hemoglobinopathies and Related Disorders (8 papers). Nicolas Martin collaborates with scholars based in France, Switzerland and United States. Nicolas Martin's co-authors include Olivier Sitbon, Marius M. Hoeper, Emmanuelle Cottreel, Caroline Even, Amaury Daste, Anne Aupérin, Christophe Le Tourneau, Khalil Saleh, Nick H. Kim and J. Guigay and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Nicolas Martin

46 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas Martin France	14	385	244	153	140	122	50	711
Sanjaykumar Hapani United States	6	362 0.9×	577 2.4×	147 1.0×	158 1.1×	74 0.6×	9	1.0k
T. Girinski France	13	163 0.4×	200 0.8×	91 0.6×	105 0.8×	55 0.5×	26	759
N. Dupouy France	10	344 0.9×	216 0.9×	57 0.4×	65 0.5×	74 0.6×	13	707
Sharon Forsyth United Kingdom	10	493 1.3×	639 2.6×	115 0.8×	242 1.7×	53 0.4×	27	1.2k
Rahul R. Parikh United States	19	388 1.0×	347 1.4×	26 0.2×	160 1.1×	53 0.4×	78	1.1k
Terenig Terjanian United States	10	182 0.5×	490 2.0×	25 0.2×	163 1.2×	159 1.3×	30	935
Vishram B. Rege United States	14	449 1.2×	484 2.0×	36 0.2×	105 0.8×	39 0.3×	19	827
Lionel Duck Belgium	11	279 0.7×	490 2.0×	30 0.2×	313 2.2×	22 0.2×	33	837
Umut Özbek United States	15	122 0.3×	280 1.1×	35 0.2×	340 2.4×	15 0.1×	49	984

Countries citing papers authored by Nicolas Martin

Since Specialization

Citations

This map shows the geographic impact of Nicolas Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Martin more than expected).

Fields of papers citing papers by Nicolas Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Martin. The network helps show where Nicolas Martin may publish in the future.

Co-authorship network of co-authors of Nicolas Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Martin. A scholar is included among the top collaborators of Nicolas Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Martin. Nicolas Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Howard, Luke, Jean Elwing, Catarina Fernandes, et al.. (2025). 10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH) from the GRIPHON Study and Its Open-Label Extension (OLE). The Journal of Heart and Lung Transplantation. 44(4). S75–S76.

Chardin, David, et al.. (2024). Total metabolic tumor volume on ¹⁸F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 12(4). e007628–e007628. 15 indexed citations

Chin, Kelly, Richard N. Channick, Nick H. Kim, et al.. (2024). Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiology and Therapy. 13(4). 775–796. 1 indexed citations

Hurtado, Maria D., et al.. (2024). Language Disparities in Patient Portal Access and Use among Radiation Oncology Patients Across an Integrated Health Enterprise. International Journal of Radiation Oncology*Biology*Physics. 120(2). e48–e49.

Kim, Nick H., Kelly Chin, Vallerie V. McLaughlin, et al.. (2024). Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies. Pulmonary Therapy. 10(1). 85–107. 5 indexed citations

Torbicki, Adam, Richard N. Channick, Nazzareno Galiè, et al.. (2024). Effect of Macitentan in Pulmonary Arterial Hypertension and the Relationship Between Echocardiography and cMRI Variables: REPAIR Echocardiography Sub-study Results. Cardiology and Therapy. 13(1). 173–190.

Chardin, David, et al.. (2024). [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. European Journal of Nuclear Medicine and Molecular Imaging. 51(12). 3696–3708. 3 indexed citations

McLaughlin, Vallerie V., Olivier Sitbon, Kelly Chin, et al.. (2024). Initial Combination Therapy with Macitentan and Tadalafil in Patients with Pulmonary Arterial Hypertension, with and without Cardiac Comorbidities. European Journal of Heart Failure. 26(11). 2379–2391. 4 indexed citations

Otto, Josiane, Pierre‐Yves Bondiau, Rabia Boulahssass, et al.. (2023). Safety and efficacy of two-drug combination in elderly patients with locally advanced non-small cell lung cancer and validation of the Charlson Index as a predictor of survival. Journal of Thoracic Disease. 15(7). 3764–3775.

10.

Saleh, Khalil, Anne Aupérin, Nicolas Martin, et al.. (2021). Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer. 157. 190–197. 10 indexed citations

11.

Noordegraaf, Anton Vonk, Richard N. Channick, Emmanuelle Cottreel, et al.. (2021). The REPAIR Study. JACC. Cardiovascular imaging. 15(2). 240–253. 33 indexed citations

12.

Galiè, Nazzareno, Olivier Sitbon, Martin Doelberg, et al.. (2020). Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study. European Heart Journal. 41(Supplement_2). 2 indexed citations

13.

Chin, Kelly, Olivier Sitbon, Martin Doelberg, et al.. (2020). Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. A2928–A2928. 14 indexed citations

14.

Rosenkranz, Stephan, Nazzareno Galiè, Richard N. Channick, et al.. (2019). EFFECTS OF MACITENTAN ON RIGHT VENTRICULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE REPAIR STUDY INTERIM ANALYSIS. Journal of the American College of Cardiology. 73(9). 1898–1898. 1 indexed citations

15.

Sitbon, Olivier, Jaime Bosch, Emmanuelle Cottreel, et al.. (2019). Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. The Lancet Respiratory Medicine. 7(7). 594–604. 111 indexed citations

16.

Saleh, Khalil, Amaury Daste, Nicolas Martin, et al.. (2019). Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer. 121. 123–129. 118 indexed citations

17.

Martin, Nicolas, Nicolás Isambert, Carlos Gomez‐Roca, et al.. (2018). Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(6). 979–986. 12 indexed citations

18.

Oza, Amit M., Frédèric Selle, Ірина Давиденко, et al.. (2016). Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. International Journal of Gynecological Cancer. 27(1). 50–58. 55 indexed citations

19.

Porter, John B., Mohsen Saleh Elalfy, Alì Taher, et al.. (2012). Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of Hematology. 92(2). 211–219. 30 indexed citations

20.

Anguita, Eduardo, et al.. (1998). [Usefulness of molecular screening in childhood lymphoblastic leukemias].. PubMed. 43(1). 7–11. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact